ClinicalTrials.gg
CompletedNCT06920056Updated Oct 13, 2026

A Study of BGM0504 in Overweight or Obese Participants

A Phase 1 interventional study of Paracetamol and Metformin Hydrochloride in Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.
Updated Oct 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 330 studies in Overweight with a site in China — 123 open to participants now, 166 under way, 43 of them phase 3. Overweight · China.

Enrollment
267th of 296
28 · median 120
Started
2025
with 65 others
Phase 1
82 of 330
25 open now
Registered
153rd of 330
by date
Lead sponsor
7 of 330
BrightGene Bio-Medical Technology Co., Ltd.

Among the 330 studies in Overweight with a site in China, this one is the 267th largest by enrollment of the 296 interventional ones that give a count, is one of 66 that started in 2025, is one of 82 in phase 1, and was the 153rd registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

123 of the 330 studies in Overweight with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 330 studies in Overweight with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the influence of BGM0504 injection on gastric emptying and Pharmacokinetics of metformin and warfarin in overweight or obese participants

03

Conditions studied

  • Overweight or Obese
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: √ Have a (BMI) of greater than or equal to (≥)28 kilogram per square meter (kg/m²) or ≥24 kg/m2 and less than (\<) 28 kg/m².

√ Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff.

Exclusion Criteria: √ History of chronic or acute pancreatitis.

  • History of severe drug allergy or specific allergic disease or severe allergies.
  • Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2(MEN-2).
  • History of malignant tumors [except carcinoma in situ with no recurrence within 5 years (except for malignant melanoma in situ), skin basal cell carcinoma and squamous cell carcinoma].
  • Suspected or confirmed history of alcohol or drug abuse;
  • Any chronic infections likely to interfere with study conduct or interpretation such as (HBV), (HCV), (HIV) or treponema pallidum (TP).
  • Donation or loss of 400 mL or more of blood within 3 months prior to screening, or blood donation during screening or within 3 months after the end of the trial.
  • Pregnant or lactating woman.
  • Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Paracetamol + Metformin + Warfarin +BGM0504

    Participants receive Paracetamol on Day1 and Day70, Metformin on Day4 and Day73, Warfarin on Day7 and Day77. Participants receive maintenance dose 10 mg (from D42 to Day 77) with dose escalation starting from 2.5 mg(on Day 14 and Day 21), 5 mg(on Day 28 and Day 35) and then 10 mg BGM0504 administered subcutaneously (SC) once weekly (QW).

    Drug: Paracetamol · Drug: Metformin Hydrochloride · Drug: Warfarin · Drug: BGM0504

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t)of Paracetamol

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Paracetamol

    Time frame: From Day1 to Day72

  2. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Paracetamol

    Pharmacokinetics (PK): Maximum observed plasma drug concentration (Cmax) of Paracetamol

    Time frame: From Day1 to Day72

  3. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Metformin

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t)of Metformin

    Time frame: From Day4 to Day76

  4. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin

    Time frame: From Day4 to Day76

  5. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Warfarin

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Warfarin

    Time frame: From Day7 to Day84

  6. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Warfarin

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Warfarin

    Time frame: From Day7 to Day84

Secondary outcomes

  1. Area Under the Stable-State Concentration Versus Time Curve (AUC0-∞,ss ) of BGM0504

    Area Under the Stable-State Concentration Versus Time Curve (AUC0-∞,ss ) of BGM0504

    Time frame: From Day14 to Day69

  2. Time to Maximum Concentration (Tmax) of Metformin and Warfarin

    Time to Maximum Concentration (Tmax) of Metformin and Warfarin

    Time frame: From Day1 to Day84

  3. Terminal Half-life (t1/2) of Paracetamol

    Terminal Half-life (t1/2) of Paracetamol

    Time frame: From Day1 to Day72

07

Study locations

1 site
  • The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine)
    Kunming, Yunnan 650100, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jul 2025, 4 months.

Of 212 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 4 months is below that.

Counting every sponsor, half of 231 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 9, 2025
StartActual
Mar 25, 2025
Primary completionActual
Jul 25, 2025
CompletionActual
Jul 25, 2025
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 24, 2025→Mar 25, 2025
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Mar 24, 2025→Mar 25, 2025
    + 1 other change: oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06920056
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
Mar 25, 2025
Primary completion
Jul 25, 2025
Completion
Jul 25, 2025
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion